Citigroup Inc Prelude Therapeutics Inc Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Citigroup Inc holds 5,975 shares of PRLD stock, worth $9,141. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,975
Previous 4,718
26.64%
Holding current value
$9,141
Previous $3,000
166.67%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $55.6M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...